Saturday, July 11, 2026

Drug profile · INN

ethynodiol diacetate

ethynodiol diacetate (OVULEN-21) is a progesterone receptor agonist. Route of administration: oral-21. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — ethynodiol diacetate
US status
approved
Class
Route
ORAL-21
Patents
0
Programs
0
Data quality
0.84

Quick answer

ethynodiol diacetate (OVULEN-21) is a progesterone receptor agonist. Route of administration: oral-21. Current US regulatory status: approved.

Key facts

INN ethynodiol diacetate
Brand OVULEN-21
Mechanism Progesterone receptor agonist
Target Progesterone receptor
Route ORAL-21
Formulation TABLET

Mechanism of action

Progesterone receptor agonist

Primary target: Progesterone receptor

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. desogestrel Progesterone receptor agonist
  2. medroxyprogesterone acetate Progesterone receptor agonist
  3. megestrol acetate Progesterone receptor agonist
  4. norethindrone Progesterone receptor agonist
  5. norethindrone acetate Progesterone receptor agonist
  6. progesterone Progesterone receptor agonist

Frequently asked questions

What is ethynodiol diacetate?

ethynodiol diacetate (OVULEN-21) is a progesterone receptor agonist. Route of administration: oral-21. Current US regulatory status: approved.

What is the brand name for ethynodiol diacetate?

OVULEN-21 is a marketed brand name for ethynodiol diacetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ethynodiol diacetate?

ethynodiol diacetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.